Roche news from FierceBiotech
NewsNovartis extends $700M Alnylam pact
Novartis has extended its pact with Alnylam through October 2009. The deal, which is worth up to $700 million Read more...
In fresh blow, Roche shutters HIV research program
In another big blow to the AIDS research field, pharma giant Roche is dumping its R&D work in the field. The Financial Times reports that disappointing clinical results had persuaded Roche to Read more...
Sangamo, Sigma-Aldrich ink Roche deal
Sangamo and Sigma-Aldrich have inked a deal with Roche for the use of zinc finger nuclease (ZFN) technology to develop cell-lines and transgenic animals that have targeted modifications in a Read more...
Roche CEO: Emphasizing drugs for primary care
The new CEO at Roche is sending out some strong signals that the pharma giant's development process will include more new therapies for primary care. Roche is a big player in the field of Read more...
Roche oncology chief sees big impact of sugar tech
Three years after plunking down $180 million to buy GlycArt, Roche says the sugar-related technology it acquired in the deal is demonstrating striking effectiveness enhancing experimental cancer Read more...
Roche signs up for $774M development pact
Roche has forged a $774 million deal to license an early stage cancer drug from Belgium's ThromboGenics and Sweden's BioInvent. In the deal, ThromboGenics gets a whopping $77.4 million upfront Read more...
Inimex raises $22M in VC
Despite a recent Ernst & Young report on the funding challenges in Canada, Inimex Read more...
SPOTLIGHT: Pertuzumab slows breast cancer in study
Roche announced that a combination of Herceptin and pertuzumab slowed the spread of breast Read more...
Roche posts new data backing Actemra for RA
Roche has racked up more late-stage data backing Actemra as a new therapy for rheumatoid arthritis. Researchers say their fifth Phase III trial demonstrated that the therapy inhibited structural Read more...
Roche expands Memory pact
Roche has exercised its option to further develop and commercialize Memory Pharmaceuticals' drug candidate, MEM 3454, for various neurological and psychiatric disorders. Memory gets a $6 million Read more...
| Press ReleasesPRESS RELEASE: Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic Summary: An IND has Been Filed With the FDA for the Fourth Genmab Antibody Developed Under the Company's Collaboration with Read more... PRESS RELEASE: FDA approves Mircera: first renal anemia treatment in the US with monthly maintenance dosing FDA approves Mircera: first renal anemia treatment in the US with monthly maintenance dosing Roche announced today that the U.S. Food and Drug Administration (FDA) has approved Mircera (methoxy Read more... PRESS RELEASE: Roche Confirms Commencement of Due Diligence with Ventana Roche Confirms Commencement of Due Diligence with Ventana Roche confirmed today that it has entered into a confidentiality agreement with Ventana Medical Systems, Inc. (NASDAQ: VMSI) and that it Read more... PRESS RELEASE: Ventana Enters into Confidentiality Agreement with Roche Ventana Enters into Confidentiality Agreement with Roche TUCSON, Ariz. -- Nov. 13, 2007--Ventana Medical Systems, the global leader in tissue-based cancer diagnostics, today announced it has entered Read more... PRESS RELEASE: Roche signs licensing and settlement agreements for Hepatitis C immunodiagnostics Roche signs licensing and settlement agreements for Hepatitis C immunodiagnostics Roche announced today licensing and settlement agreements with Ortho-Clinical Diagnostics, Inc. and Novartis Read more... |
Get more Roche coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets